Skip to main content
main-content

09-12-2019 | Haematology | Video

ASH 2019: Clinical benefit with CAR T-cell therapy in mantle cell lymphoma

Brian Hill discusses the phase 2 ZUMA-2 trial looking at the response to KTE-X19 in patients with relapsed or refractory mantle cell lymphoma (3:42).

Funding for independent interviews at ASH 2019 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits